Search

Your search keyword '"García‐Sancho, A. Martín"' showing total 3 results
Start Over Author "García‐Sancho, A. Martín" Publisher american society of clinical oncology
3 results on '"García‐Sancho, A. Martín"'

1. Supplementary files of the article Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial [Dataset]

Author

Gine, Eva, Cruz, Fátima de la, Jiménez-Ubieto, Ana, López Jiménez, Javier, García-Sancho, Alejandro Martín, Terol, María José, González-Barca, Eva, Casanova, María, Fuente, Adolfo de la, Marín-Niebla, Ana, Muntañola, Ana, González-López, Tomás J., Aymerich, Marta, Setoain, Xavier, Cortés-Romera, Montserrat, Rotger, Amanda, Rodríguez, Sonia, Medina, Alejandro, García-Sanz, Ramón, Nadeu, Ferran, Beà, Silvia, Campo, Elías, López-Guillermo, Armando, Gine, Eva, Cruz, Fátima de la, Jiménez-Ubieto, Ana, López Jiménez, Javier, García-Sancho, Alejandro Martín, Terol, María José, González-Barca, Eva, Casanova, María, Fuente, Adolfo de la, Marín-Niebla, Ana, Muntañola, Ana, González-López, Tomás J., Aymerich, Marta, Setoain, Xavier, Cortés-Romera, Montserrat, Rotger, Amanda, Rodríguez, Sonia, Medina, Alejandro, García-Sanz, Ramón, Nadeu, Ferran, Beà, Silvia, Campo, Elías, and López-Guillermo, Armando more...

Published
2022

2. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Author

Instituto de Salud Carlos III, Fundació La Marató de TV3, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), National Institutes of Health (US), European Commission, Fundacion de la Sociedad Española de Hematología y Hemoterapia, Gine, Eva, Cruz, Fátima de la, Jiménez-Ubieto, Ana, López Jiménez, Javier, García-Sancho, Alejandro Martín, Terol, María José, González-Barca, Eva, Casanova, María, Fuente, Adolfo de la, Marín-Niebla, Ana, Muntañola, Ana, González-López, Tomás J., Aymerich, Marta, Setoain, Xavier, Cortés-Romera, Montserrat, Rotger, Amanda, Rodríguez, Sonia, Medina, Alejandro, García-Sanz, Ramón, Nadeu, Ferran, Beà, Silvia, Campo, Elías, López-Guillermo, Armando, Instituto de Salud Carlos III, Fundació La Marató de TV3, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), National Institutes of Health (US), European Commission, Fundacion de la Sociedad Española de Hematología y Hemoterapia, Gine, Eva, Cruz, Fátima de la, Jiménez-Ubieto, Ana, López Jiménez, Javier, García-Sancho, Alejandro Martín, Terol, María José, González-Barca, Eva, Casanova, María, Fuente, Adolfo de la, Marín-Niebla, Ana, Muntañola, Ana, González-López, Tomás J., Aymerich, Marta, Setoain, Xavier, Cortés-Romera, Montserrat, Rotger, Amanda, Rodríguez, Sonia, Medina, Alejandro, García-Sanz, Ramón, Nadeu, Ferran, Beà, Silvia, Campo, Elías, and López-Guillermo, Armando more...

Abstract

[Puropose]: The need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant responses in these patients., [Methods]: This is a multicenter single-arm, open-label, phase II study with a two-stage design conducted in 12 Spanish GELTAMO sites (ClinicalTrials.gov identifier: NCT02682641). Previously untreated MCL patients with indolent clinical forms defined by the following criteria were eligible: no disease-related symptoms, nonblastoid variants, Ki-67 < 30%, and largest tumor diameter ≤ 3 cm. Both leukemic non-nodal and nodal subtypes were recruited. Patients received ibrutinib 560 mg once daily and a total of eight doses of rituximab 375 mg/m2. Ibrutinib could be discontinued after 2 years in the case of sustained undetectable minimal residual disease (MRD). The primary end point was the complete response (CR) rate achieved after 12 cycles according to Lugano criteria., [Results]: Fifty patients with MCL (male 66%; median age 65 years) were enrolled. After 12 cycles of treatment, 42 (84%; 95% CI, 74 to 94) patients had an overall response, including 40 (80%; 95% CI, 69 to 91) with CR. Moreover, undetectable MRD in peripheral blood was achieved in 87% (95% CI, 77 to 97) of cases. At 2 years, 24 of 35 evaluable patients (69%) could discontinue ibrutinib because of undetectable MRD. Four patients had disease progression; three were non-nodal MCL and carried high genomic complexity and TP53 mutations at enrollment. No unexpected toxicity was seen except one patient with severe aplastic anemia., [Conclusion]: Frontline IR combination achieves a high rate of CRs and undetectable MRD in indolent clinical forms of MCL. Discontinuation seems appropriate in cases with undetectable MRD, except for TP53-mutated cases. more...

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results

3. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).

Author

Bachy, Emmanuel, Camus, Vincent, Thieblemont, Catherine, Sibon, David, Casasnovas, René-Olivier, Ysebaert, Loïc, Damaj, Gandhi, Guidez, Stéphanie, Pica, Gian Matteo, Kim, Won Seog, Lim, Soon Thye, André, Marc, García-Sancho, Alejandro Martín, Penarrubia, Maria Jesus, Staber, Philipp B, Trotman, Judith, Hüttmann, Andreas, Stefoni, Vittorio, Re, Alessandro, and Gaulard, Philippe more...

Published
2022
Full Text
View/download PDF